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Abstract
Background: Since the end of 2011 an outbreak of pseudorabies affected Chinese pig herds that had been
vaccinated with the commercial vaccine made of Bartha K61 strain. It is now clear that the outbreak was caused by an
emergent PRV variant. Even though vaccines made of PRV Bartha K61 strain can confer certain cross protection against
PRV variants based on experimental data, less than optimal clinical protection and virus shedding reduction were
observed, making the control or eradication of this disease difficult.
Results: An infectious clone of PRV AH02LA strain was constructed to generate a gE deletion mutant PRV(LA-AB)
strain. PRV(LA-AB) strain can reach a titer of 108.43 TCID50 /mL (50% tissue culture infectious dose) on BHK-21 cells.
To evaluate the efficiency of the inactivated vaccine made of PRV(LA-AB) strain, thirty 3-week-old PRV-negative
piglets were divided randomly into six groups for vaccination and challenge test. All five piglets in the challenge
control showed typical clinical symptoms of pseudorabies post challenge. Sneezing and nasal discharge were
observed in four and three piglets in groups C(vaccinated with inactivated PRV Bartha K61 strain vaccine) and
D(vaccinated with live PRV Bartha K61 strain vaccine) respectively. In contrast, piglets in both groups A(vaccinated
with inactivated PRV LA-AB strain vaccine) and B(vaccinated with inactivated PRV LA-AB strain vaccine with adjuvant)
presented mild or no clinical symptoms. Moreover, viral titers detected via nasal swabs were approximately 100 times
lower in group B than in the challenge control, and the duration of virus shedding (3–4 days) was shorter than in
either the challenge control (5–10 days) or groups C and D (5–6 days).
Conclusions: The infectious clone constructed in this study harbors the whole genome of the PRV variant AH02LA
strain. The gE deletion mutant PRV(LA-AB)strain generated from PRV AH02LA strain can reach a high titer on BHK-21
cells. An inactivated vaccine of PRV LA-AB provides clinical protection and significantly reduces virus shedding post
challenge, especially if accompanied by the adjuvant CVC1302. While Inactivated or live vaccines made of PRV Barth
K61 strain can provide only partial protection in this test.
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Background
Pseudorabies, caused by pseudorabies virus(PRV), has
leaded to significant economic losses to the pig industry in
many countries. Pseudorabies is a porcine infectious dis-
ease that can be effectively controlled using gene deletion
marked vaccines and serum monitoring, enabling differen-
tiation of vaccinated from infected animals [1–3]. However,
in 2011 an outbreak of pseudorabies affected Chinese pig
herds that had been vaccinated with the standard PRV
Bartha K61 strain [4–9]. It is now clear that the outbreak
was caused by an emergent PRV variant [5–7, 9–13].
As a support for this finding, the widely used PRV
Bartha K61 strain was shown to be incapable of pro-
viding complete protection against this new PRV vari-
ant in several experimental studies [4–8]. Thus, a more
efficacious vaccine is perceived as a necessary tool to help
affected herds revert to PRV virus negative status.
To develop an effective vaccine, gene deletion mutants
were generated from the new PRV strain and evaluated
for protection efficacy. Although live vaccine candidates
based on gE, gE/gI, or TK/gE/gI gene deletion mutants
are assumed to be highly protective, the safety issues of
these preparations have to be demonstrated by lengthy
testing [4, 14–18]. Alternatively, inactivated version of
vaccine from the same mutants are promising to provide
clinical protection as well based on relevant data about
inactivated Bartha strain.
In this study, LA-AB, a gE deleted mutant of the emer-
ging PRV strain AH02LA, was constructed using a bac-
terial artificial chromosome clone. A vaccine utilizing
this mutant was evaluated with and without adjuvant in
regard to its ability to provide clinical protection and re-
duce virus shedding after lethal challenge.
Methods
Cells and viruses
BHK-21 cells (CVCC:CL5, from China Veterinary Culture
Collection Center) and chicken embryo cells (CECs) (SPF
chicken embryo eggs were from Beijing Merial Vital
Laboratory Animal Technology Co., Ltd) were pre-
pared using standard methods. The PRV Bartha K61
strain was kindly provided by Professor Ping Jiang of
Nanjing Agricultural University. Virus cultures and
stocks were prepared using CECs or BHK-21 cells before
at -70 °C. Virus titers were determined by TCID50 on
BHK-21 cells following a standard protocol. Viral DNA
extraction and transfection of plasmid, virus or bacterial
artificial chromosome(BAC) DNAs were performed as de-
scribed previously [19, 20].
Plasmid and BAC manipulation
The mini-F transfer vector pHA2-pUC19-H1-H2 was
constructed as described [16]. Plasmid and BAC DNAs
were isolated using commercial kits (Invitrogen PureLink®
Quick Plasmid Miniprep and Qiagen Large-Construct Kit)
following the manufacturer’s instructions. Next, restriction
fragment length polymorphism(RFLP) analyses of PRV
BACs was conducted using the restriction endonucleases
BamH I, Kpn I, Pst I and Sph I and digestion conditions
recommended by the supplier (Takara). Electrocompetent
E.coli cells (DH10B) were obtained commercially (Invitro-
gen). E.coli GS1783 was made electrocompetent using
published protocols [21–23]. Electroporation was per-
formed to transform viral or BAC DNA following estab-
lished methods [23–25].
PCR and sequencing
A pair of primers (Table 1) was designed from reference
sequence (GenBank:NC_006151.1) to amplify sequences
Table 1 Primers for PCR or sequencing
Primer Sequence
PRV gD F 5’-AACACCTAATTTGCGTACGGC-3’
PRV gD R 5’-TCATCATCGACGCCGGTACT-3’
PRV gI F 5’-TGGGCGTGTGCGTCTACATCT-3’
PRV gI R 5’-CAACCCCGGTGTGTGTGAGA-3’
ΔgE TV overlap1 F 5’-CCACGCCCAGCGGTCCATAAAATTGGGT-3’
ΔgE TV overlap1 R 5’- TCATCACGAAGGAGCCCAGCAAAGGG
CCGCATGG TCTCAACC-3’
ΔgE TV overlap2 F 5’-GCTGGGCTCCTTCGTGATGA-3’
ΔgE TV overlap2 R 5’-TCACGATCTGGGCATGCAGG-3’
SEQ-gI/gE F 1 5’-TTGCGTACGGCCTTGCTTAC-3’
SEQ-gI/gE F 2 5’-GACTACATGTTCCCCACGGA-3’
SEQ-gI/gE F 3 5’-ACGCCGTACGCCATCGACCC-3’
SEQ-gI/gE F 4 5’-ACGCTGCTGTTTCTGGAGGG-3’
SEQ-gI/gE F 5 5’-ACGAAGAGGAGGAGGACGAG-3’
SEQ-gI/gE F 6 5’-ACCATGCGGCCCTTTCTGCT-3’
SEQ-gI/gE F 7 5’-ACCACGGTGTGCTTCGAGAC-3’
SEQ-gI/gE F 8 5’-TGTACGAGCCCTGCATCTACCACCC-3’
SEQ-gI/gE F 9 5’-ACTACTACGACGGCGACGACGACGA-3’
SEQ-gI/gE F 10 5’-AACGAGACGCCCAGCGAGTT-3’
SEQ-gI/gE F 11 5’-AAGGTGCTCACCGAGTGGTGCTACG-3’
SEQ-gI/gE R 1 5’-TCTAGGAGATGGTACATCGCGGGGC-3’
SEQ-gI/gE R 2 5’-TGGTGATGTAGAACGGCGCC-3’
SEQ-gI/gE R 3 5’-ACAGCGAGCAGATGACCAGC-3’
SEQ-gI/gE R 4 5’-TCGCTGCTGAACTCGTCCTC-3’
SEQ-gI/gE R 5 5’-ATCACGAGCACGTACAGCCC-3’
SEQ-gI/gE R 6 5’-TGTAGAGGCCCGTGTCGTTG-3’
SEQ-gI/gE R 7 5’-AAAGGGCCGCATGGTCTCAACC-3’
SEQ-gI/gE R 8 5’-TCCTCCTCCTCTTCGTCGGA-3’
SEQ-gI/gE R 9 5’-AAAGAGGTCCGTGGTCCCGTTCAC-3’
SEQ-gI/gE R 10 5’-AGATGTAGACGCACACGCCCACCAG-3’
SEQ-gI/gE R 11 5’-GGGAACATGTAGTCCGCGGA-3’
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of gI gene with isolated PRVAH02LA strain DNA as tem-
plate. These primers were also used for sequencing gI
gene (GeneScript, Nanjing China). To obtain the gE dele-
tion, overlap PCR was conducted with two pairs of
primers, ΔgE TV overlap1 and ΔgE TV overlap2 (Table 1).
Briefly, with PRVAH02LA DNA as template, two PCR re-
actions were performed separately with the above two pri-
mer pairs. Next, the PCR products were gel purified to
serve as templates in another PCR reaction with primers
ΔgE TV overlap1 F and ΔgE TV overlap2 R to produce a
fragment for gE deletion mutant generation. Thus the
generated mutant, consists of upstream sequences, the in-
tact gI gene, part of gE gene(1299 bp to 1735 bp of gE
ORF), and downstream sequences (Fig. 1). Finally, the
primers PRV Homo-1 F and PRV Homo-2R [16] were
used to amplify the repairing viral DNA with the PRV
AH02LA DNA as template.
Multistep growth kinetics
Multistep growth kinetics of parental AH02LA, gE dele-
tion LA-AB, and repair AH02LAR viruses were tested on
BHK-21 cells following methods as described [26] on
monolayers (1 × 106 cells) of BHK-21 cells with a multi-
plicity of infection(MOI)of 0.01. Three independent ex-
periments were conducted and one-way ANOVA (SPSS
software package) was employed to identify significant
differences.
LD50 determination for PRV AH02LA strain
To determine the LD50 of the virulent PRV AH02LA
strain, the virus (TCID50 = 10
-8.25/mL) was serially di-
luted with DMEM to 10-1, 10-2, 10-3 and 10-4. Twenty-
five 77-day-old piglets were randomly divided into five
groups. Piglets in each challenge group were inoculated
intranasally(I.N.) with 1 mL diluted virus of different ti-
ters. Animals were observed for additional fourteen days.
The number of piglets that died in each group was re-
corded to calculate LD50 using the Karber method.
Construction of PRV BAC and deletion mutants
The PRV BAC was constructed from an isolate of the
emergent PRV variant following published methods (Fig. 1)
[16, 26]. Briefly, After cotransfection of ~1.5 μg PRV
AH02LA strain DNA and ~4 μg pHA2-pUC19-H1-H2
DNA, mini-F recombinant viruses with green fluorescence
were purified to obtain a homogeneous population [27].
Next, mini-F containing PRV DNA was isolated and then
transferred into E. coli cells DH10B and subsequently into
E.coli strain GS1783 cells by electroporation for mutagen-
esis [23]. Finally, BAC DNA was isolated and RFLPs were
identified as described [24] using BamH I, Kpn I, Pst I and
Fig. 1 Construction of mini-F recombinant PRV AH02LA strain and its gE deletion mutant virus (LA-AB). a The whole genome of PRV. b Homologous
recombination was conducted to insert mini-F in lieu of gI and gE to generate the mini-F recombinant PRV AH02LA strain for BAC construction.
c Another recombination was performed to recover the whole gI gene and part of gE gene, the resulting BACPRV-G was used to generate the gE
deletion LA-AB strain. Scales in bp or kbp are provided
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Sph I, using the complete genome sequence of PRV ZJ01
strain (GenBank: KM061380.1) as a reference for in silico
prediction.
To generate the gE deletion mutant of PRV AH02LA
strain, another homologous recombination was per-
formed to recover the gI gene and the undeleted se-
quences of gE as shown in Fig. 1. Briefly, PCR with
primers ΔgE TV overlap1 F and ΔgE TV overlap2 R
(Table 1) was performed with the PRV AH02LA DNA as
template. And then CECs were co-transfected with ap-
proximately 5 μg PRV BAC DNA and 2 μg DNA of frag-
ment from the second PCR reaction of overlap PCR
with primersΔgE TV overlap1 F andΔgE TV overlap2 R
by calcium phosphate precipitation. Using illumination
at 488 nm, non-fluorescent virus isolates were selected
and purified to homogeneity. Product structure was con-
firmed by sequencing with the same primers and other
specific primers from the SEQ-gI/gE series (Table 1).
For generation of the gI/gE repair virus via homolo-
gous recombination, CECs were transfected with ap-
proximately 5 μg PRV BAC DNA and 2 μg PCR product
generated using DNA of parental PRV as template and
primers matching PRV Homo 1 F and PRV Homo 2R
[16] (Fig. 1). Two to three days after transfection, non-
fluorescent plaques (488 nm) were isolated and purified
to obtain a homogeneous population. The structure of
the recovered viruses was confirmed by PCR and se-
quencing with primers PRV Homo 1 F, PRV Homo 2R
and sequencing primers of SEQ-gI/gE (Table 1).
Preparation of vaccine
PRV LA-AB and Bartha K61 viruses were propagated in
BHK-21 cells using a 5 liter bioreactor, each virus stock
was diluted to 108.5 TCID50/mL. After inactivation with
formalin (Sigma-Aldrich) as described [16], vaccines were
prepared using mineral oil adjuvant (1:3 water in oil). All
vaccines were confirmed to be free of bacteria and fungi,
and had the expected physical properties according to
standard protocols. Vaccines were stored at 4 °C until use.
Test of vaccine efficacy
Thirty piglets of 21-day-old (from Zhengzhuquan Pig
Breeding Farm in Pukou district, Nanjing, China) were
randomly divided into 6 groups (A-F) and housed in
separated facilities. All piglets were antibody negative for
PRV gB and gE, and free of porcine reproductive and re-
spiratory syndrome virus, porcine parvovirus, porcine
circovirus 2 and classical swine fever virus. All inocula-
tions were given intramuscularly(I.M.) at 2 mL/pig.
Group A piglets were inoculated with LA-AB, group B
piglets with LA-AB plus adjuvant CVC1302 (Patent:
CN103083663B, kindly provided by the group of Dr.
Qisheng Zheng in our institute), group C piglets with
inactivated Bartha K61, group D piglets with live Bartha
K61 of 1 × 105.0 TCID50 virus/dose, and groups E and F
piglets were dosed with PBS only. Piglets in groups A, B,
and C were inoculated at 28 days of age and again at
56 days. Group D piglets were inoculated once, at 28-day-
old. Group E and F piglets were dosed once, at 28 days of
age. Three weeks after the second inoculation (at which
time the piglets were 11-week-old), groups A, B, C, D and
E were challenged I.N. with 3 × LD50 PRV AH02LA per
piglet. Group F piglets were not challenged, serving as a
negative control. Serum samples from all piglets were col-
lected before inoculation, and at 7, 14, 21, 28, 35, 42 and
49 days post inoculation, and again at 14 days post challen-
ge(P.C.). Serum was subjected to ELISA tests for PRV gB
and gE antibodies, and cross-neutralizing (NA) antibodies
against AH02LA or Bartha K61. Body temperature, clinical
signs, and virus shedding were monitored and recorded
daily until 14 days P.C.. The presence of lung lesions for
died or survived piglets was noted at the end of the test.
Test for serological antibodies
ELISA tests were performed with the PRV gE or gB anti-
body detection kit (IDEXX, Maine, USA) following man-
ufacturer’s instructions. Cross neutralization tests were
conducted according to the standard methods published
by OIE (Veterinary Pharmacopoeia of the People's Re-
public of China (2010)) with slight modification. Briefly,
serum samples were diluted two-fold with PBS, mixed
with 100 TCID50 PRV AH02LA or PRV Bartha K61
virus, and incubated for 1 h at 37 °C. The serum-virus
mixture was used to inoculate BHK-21 cells which were
then incubated at 37 °C, 5% CO2 for 3–4 days to observe
the development of CPE. Titers of neutralizing antibody
were expressed as nlog2 of highest dilution at which no
CPE was observed, and mean titers of each group were
calculated for comparison.
Detection of virus shedding
Nasal swab samples were collected from all piglets be-
fore challenge and daily to 14 days after challenge. After
shaking at 5000–8000 RPM for 1–2 min, one freeze-
thaw cycle (-70 °C and 37 °C) was conducted to release
viruses from nasal swabs. Samples were centrifuged at
10,000 RPM for 15 min to pellet tissue and cell debris,
the supernatants were collected to determine virus titers.
Viruses titers were expressed as TCID50 following the
method of Karber.
All animal studies were conducted following guidelines
provided by the Institutional Biosafety Committee and
approved by the Institutional Animal Care and Use
Committee at the Jiangsu Academy of Agriculture Sci-
ences. Experiments involving virulent PRV were con-
ducted under Biosafety Level 2+ containment.
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Results
Isolation and identification of an emergent pseudorabies
virus variant (AH02LA strain)
BHK-21 cells, inoculated with a sample of brain tissue
from a stillborn piglet, exhibited cytopathogenic effects
(CPE) after 3 days. After three rounds of plaque purifica-
tion, a homogeneous population of virus was isolated
and designated as the AH02LA strain. Using the viral
DNA as template and the primers PRV gI F/ R (Table 1),
PCR generated a product of 1250–1400 bp. Sequencing
established that this fragment was homologous to the
PRV gI gene. The AH02LA strain can be specifically
neutralized with the standard antibodies against PRV
(CIVDC, Beijing China) with a neutralizing index of
10,000. These results demonstrate that a variant PRV
field isolate was identified.
Pathology of the PRV AH02LA strain
The LD50 of PRV AH02LA (Batch: JJ-R5) was deter-
mined using 77-day-old piglets free of antibodies against
PRV. Three of five piglets in the 10-5 dosage group, and
all of the piglets in the 10-4 dosage group, showed typical
symptoms of PRV infection: sneezing, purulent nasal
discharge, difficulty in breathing and ataxia, indicating
the high virulence of this strain. The LD50 was 10
-2.32/
mL. The highly virulent character of AH02LA is shared
by other emergent PRV strains isolated during the 2011
outbreaks [4–8]. The significant difference between
these emerging strains and the conventional strain S
(HWBD, Harbin China) is that the former cause mortal-
ities in not only young piglets but also much older pigs,
whereas the conventional strain S causes death only in
young (less than 15-day-old) piglets (Veterinary
Pharmacopoeia of the People's Republic of China
(2005)).
Construction of a bacterial artificial chromosome
containing the AH02LA genome
Green plaques of mini-F recombinant PRV AH02LA
were observed under UV light (488 nm), and isolated
after several rounds of plaque purification. The mini-F
recombinant PRV AH02LA DNA was isolated and trans-
fected into Escherichia coli DH10B competent cells, the
resulting clone was designated BACPRV-AH02LA. BACPRV-
AH02LA DNA was electroporated into E. coli GS1783
competent cells, resulting in a clone designated BACPRV-G.
This BAC was used for further gene manipulations using
the En Passant protocol [20]. Restriction fragment length
polymorphism (RFLP) analysis of BACPRV-G with BamH I,
Kpn I, Pst I and Sph I generated patterns similar to those
predicted from the PRV ZJ01 strain sequence (GenBank:
KM061380.1) with minor differences (Fig. 2). Virus was
rescued successfully by transfection of the BACPRV-G
DNA into primary CECs, designated PRV AH02LAR. In
summary, an infectious clone containing the complete
genome of the PRV emerging variant AH02LA strain was
constructed successfully.
Fig. 2 Plaques of mini-F recombinant PRV AH02LA strain and RFLP of BACPRV-G. a Images of mini-F recombinant PRV AH02LA and the parental
AH02LA plaques under UV excitation (upper) and phase contrast (lower) are shown. Arrowhead shows a plaque of parental PRV AH02LA virus
and arrow shows a plaque formed by mini-F recombinant PRV AH02LA. Each panel represents a view of 200 × 200 μm in size. b RFLP of BACPRV-G,
DNA from PRV AH02LA BAC clone BACPRV-G was prepared by mini-prep and digested with BamH I, Kpn I, Pst I and Sph I (lanes 1–4). The digests
were separated by 0.8% agarose gel electrophoresis for 16 h under 40 V (Left). Predicted RFLP patterns of BACPRV-G with BamH I, Kpn I, Pst I and
Sph I digestion respectively. Predictions of these digestions were performed with the whole genome sequence of PRV ZJ01 strain (GenBank:
KM061380.1) as reference. M: DL 15,000 DNA Marker (Takara)
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Construction of a gE deletion mutant virus
After co-transfection of BACPRV-G DNA with a DNA
fragment containing the gE deletion (obtained through
PCR), several white plaques were observed under UV il-
lumination at 488 nm. One was isolated after several
rounds of plaque purification and designated PRV LA-
AB. The deletion was verified by PCR using primers of
ΔgE TV overlap1 F andΔgE TV overlap2 R, followed by
sequencing with the appropriate primers (Table 1).
Growth kinetics of the PRV LA-AB virus
Multistep growth kinetics for the PRV LA-AB, AH02LA,
and AH02LAR viruses were determined. Peak super-
natant titers for LA-AB, AH02LA, and AH02LAR were
108.18, 109.01, and 108.19 TCID50 /mL respectively. At 48
hpi the titers for LA-AB and AH02LAR were not signifi-
cantly different from AH02LA (p = 0.414 and 0.362). For
cell-associated virus titers LA-AB, AH02LA, and
AH02LAR were 108.43, 108.86, and 108.13 TCID50 /mL at
48 hpi, respectively. The titers of LA-AB and AH02LAR
are not significant different from the parental virus
AH02LA at 48 hpi (p = 0.126 and 0.088).
Immunogenicity of the LA-AB vaccine
In challenge control group, all piglets had typical clinical
syndromes of pseudorabies infection including sneezing,
coughing, difficulty breathing and nasal discharge P.C..
Two piglets died at 7 days and two at 8 days P.C. (Table 2).
Body temperatures of these piglets reached over 41 °C and
lasted for 4–5 days (Fig. 3(a)). All the piglets shed virus
with titers of 100.25 ~ 105.25 TCID50 /0.1 mL lasting for 5–
7 days till death or 10 days for the surviving piglet
(Fig. 3(b)). All piglets showed severe lung lesions from
hemorrhaging and congestion (Table 2).
gB antibodies were detected in all piglets vaccinated
with live Bartha K61 strain or the LA-AB strain plus ad-
juvant at 7 days post vaccination(P.V.), while two of five
piglets vaccinated LA-AB strain alone or the inactivated
Bartha K61 strain were anti-gB positive at 7 days P.V..
All samples collected at 14 days P.V. were positive for
gB antibodies (Table 2). This result indicates the adju-
vant CVC1302 helps the LA-AB vaccine stimulate im-
munity against PRV more quickly. At 14 days P.C. all
piglets were positive for gE antibodies (Table 2).
No neutralizing antibodies (NA) against the AH02LA or
Bartha K61 strain, were detected in any of the piglets at
7 days P.V.. At 14 days P.V. neutralizing antibodies were
detected in one piglet from group B (LA-AB plus adju-
vant) at a titer of 2. In groups A, B, and C, NA titers began
increasing quickly seven days after the boost and contin-
ued to increase over the next two weeks. The LA-AB vac-
cines induced higher titers of NA against the AH02LA
and Bartha K61 strain, than vaccines made of Bartha K61.
One dose of live Bartha K61 vaccine stimulated a weak
NA titer of less than 4 against the AH02LA strain or the
Bartha K61 strain. These results indicate that optimizing
the prime-boost regimen is necessary for live Bartha K61
vaccine to stimulate strong humoral immunity. NA titers
in group B piglets were higher than other groups, indicat-
ing that adjuvant CVC1302 helped stimulate higher spe-
cific immunity for LA-AB vaccine (Table 2).
All piglets in the vaccinated groups (A, B, C and D)
were protected against lethal challenge. Fevers in group
A and B piglets were transient, and other clinical symp-
toms were mild or absent respectively. Titers of shed
virus in LA-AB vaccinated group A piglets were 100.25 ~
103.75 TCID50/0.1 mL lasting 3–4 days; in LA-A
B plus
adjuvant group B piglets, titers were 100.125 ~ 102.875
TCID50/0.1 mL lasting 3–4 days. Piglets in groups C and
D (vaccinated with inactivated Bartha K61 and live
Bartha K61 respectively) presented fevers of more than
41 °C lasting for 4–6 days (Fig. 3(a)), four and three pig-
lets respectively, presented sneezing lasting for 2–4 days
and nasal discharge lasting 2–3 days (Table 2). The titers
of shed virus in these piglets were 100.125 ~ 104.125
TCID50 /0.1 mL lasting for 5–6 days (Fig. 3(b)). No Lung
lesions were observed in any group A or B piglets, while
2/5 group C piglets and in 1/5 group D piglets presented
lesions from hemorrhage and congestion (Table 2).
Discussion
The results of vaccination test demonstrate that vaccines
made of PRV LA-AB elicit a more effective immune re-
sponse against the emergent PRV AH02LA than the
Bartha K61 vaccines. The immune response is even more
pronounced when PRV LA-AB is administered with adju-
vant. Pigs vaccinated with LA-AB produced lower titers of
virus shedding over a shorter duration than pigs with
Bartha K61. This is a clear advantage in the terms of con-
trolling the spread of infection. Adjuvant CVC1302 is a
mixture of monophosphoryl lipid A (MPLA), muramyl di-
peptide (MDP) and β-glucan. This mixture has been
shown to improve the efficiency of the inactivated vac-
cines of porcine epidemic diarrhea virus and foot and
mouth disease virus (Patent:CN103083663B). MPLA,
MDP and β-glucan can serve as delivery systems or stimu-
lators for the immune system [28–31].
Bacterial artificial chromosome(BAC) of herpesvirus is
a useful tool for generation of gene modified mutants to
study the mechanism of the viruses. After the construc-
tion of the first BAC of mouse cytomegalovirus
(MCMV) [32], a few of herpesvirus genomes have been
maintained in BACs as infectious clones, which have
provided great help for discovery of pathology of these
viruses [27, 33] and construction of vectored vaccines
[26, 34, 35], especially following the protocol of En Pas-
sant protocol [23]. The parental PRV AH02LA strain of
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the BAC constructed in this study is a virulent variant
strain that caused severe losses in many porcine farms in
China. So even though En Passant protocol was not per-
formed in the generation of the gE deleted LA-AB strain
in this study, it will be used for further analysis of the
mechanism of the high virulence of this variant.
The latent infection of PRV is always a potential threat
to porcine herds [36]. So the eradication of PRV has been
a direct aim of many farms for control of this disease. This
aim has been achieved in a few countries [1] and the infec-
tion of wild PRV has been controlled to very low levels in
some individual farms in China before 2011 [37, 38].
DIVA vaccine(vaccine allowing differentiating infected
from vaccinated animals) has played an important
role towards this aim [1]. In the project of eradication
of PRV, the efficient reduction of virus shedding post
infection with virulent strain is crucial [2]. In this
study, the inactivated vaccine of LA-AB strain with
adjuvant CVC1302 reduced virus shedding signifi-
cantly, despite that all vaccinated animals did not
stop virus shedding post challenge.
We did find a difference in the profile of clinical symp-
toms between animals challenged through I.M. or I.N.
route. During the challenge test in this study, we also
tried the challenge route of I.M. injection for 11-week-
old piglets (data not shown). We found that even though
it caused high fever and obvious clinical syndromes of
PR through this way, the virulence was significantly
Table 2 Antibodies, clinical signs and lung lesions in animals
Groups A B C D E F
ELISA antibodies against
PRV gB or gE
B.V. gB+ 0a/5b 0/5 0/5 0/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5 0/5 0/5
7d P.V. gB+ 2/5 5/5 2/5 5/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5 0/5 0/5
14d P.V. gB+ 5/5 5/5 5/5 5/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5 0/5 0/5
21d P.V. gB+ 5/5 5/5 5/5 5/5 0/5 0/5
gE+ 0/5 0/5 0/5 0/5 0/5 0/5
14d P.C. gB+ 5/5 5/5 5/5 5/5 2/2 0/5
gE+ 5/5 5/5 5/5 5/5 2/2 0/5
Mean titers of
neutralizing antibodies
AH02LA B.V. <2c <2 <2 <2 <2 <2
7d P.V. <2 <2 <2 <2 <2 <2
14d P.V. <2 0.4 <2 <2 <2 <2
21d P.V. 2.00 2.80 <2 1.20 <2 <2
28d P.V. 2.60 3.40 2.40 2.60 <2 <2
35d P.V. 4.60 5.20 3.60 3.20 <2 <2
42d P.V. 4.60 5.60 3.80 3.20 <2 <2
49d P.V. 5.20 6.20 4.20 3.00 <2 <2
Bartha K61 B.V. <2 <2 <2 <2 <2 <2
7d P.V. <2 <2 <2 <2 <2 <2
14d P.V. <2 0.4 <2 <2 <2 <2
21d P.V. 1.20 2.24 1.2 1.60 <2 <2
28d P.V. 2.40 3.08 2.60 3.20 <2 <2
35d P.V. 4.60 4.80 4.60 3.20 <2 <2
42d P.V. 4.80 5.20 4.80 3.60 <2 <2
49d P.V. 5.40 5.60 5.20 3.40 <2 <2
Clinical signs and lung
lesions post challenge
Morbidity 1/5 0/5 4/5 3/5 5/5 0/5
Duration of clinical signs(days) 1 - 2–4 2–3 4–7 -
Mortality 0/5 0/5 0/5 0/5 4/5 0/5
Lung lesions 0/5 0/5 2/5 1/5 5/5 0/5
B.V means before vaccination, P.V means post vaccination, P.C means post challenge. “a” indicates the number of piglets positive;“b” indicates the number of
piglets in the group. “c” indicates mean titers of neutralizing antibody of each group expressed as nlog2 of highest dilution at which no CPE was observed
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lower than through I.N. way. This difference is pre-
sumed to be associated with the increased titers of virus
after replication on epithelial cells of respiratory tract.
To mimick the nature infection of domestic pigs genu-
inely, we did the challenge protection test through I.N.
way for evaluation of the vaccines in this study.
Conclusion
The infectious clone consists of the whole genome of PRV
emerging variant AH02LA strain. Inactivated vaccine
made of PRV LA-AB strain can provide better clinical pro-
tection than vaccines made of Bartha K61. In addition, sig-
nificant decrease of virus shedding was observed post
lethal challenge when LA-AB inactivated vaccine were
adjuvanted with CVC1302.
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